30 December 2024-Orion Corporation and Marinus Pharmaceuticals, Inc. have decided to mutually terminate their European wide marketing and distribution agreement for ganaxolone. Marinus regains ganaxolone’s commercial rights in… read more.
Merck Inc., ( known as MSD outside of the United States and Canada), announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted… read more.
Newly published research suggests an association between COVID-19 infection and accelerated kidney function decline, especially among people who had been hospitalized for the infection. The findings were published… read more.
Cleveland Clinic researchers have found definitive proof of a kidney microbiome that influences renal health and kidney stone formation, demonstrating that the urinary tract is not sterile and low levels… read more.
Type 2 diabetes can lead to diabetic kidney disease, but a class of drugs that cause the kidneys to remove glucose through urine has been gaining attention. An… read more.
Researchers from West China Hospital, Sichuan University, have revealed a significant association between COVID-19 and acute kidney disorders (AKD), including acute kidney injury (AKI), that varies over time…. read more.
Travere Therapeutics, Inc., announced that the Company will present 11 abstracts, including one late-breaking abstract at the upcoming American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, CA, October 23-27,… read more.
Whether dialysis is the best option for kidney failure and, if so, when to start, may deserve more careful consideration, according to a new study. For older adults… read more.
A new study from UC Davis Health could help to increase the supply of donor kidneys. Researchers have found that transplant patients who receive kidneys infected with the parasite toxoplasma… read more.
Novartis announced that the FDA has granted accelerated approval for Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy… read more.
Combination treatment of diabetes with a sodium glucose co-transporter 2 inhibitor (SGLT2) and a glucagon-like peptide-1 receptor agonist (GLP1-RA) appears to also offer protection against heart and kidney… read more.
Aurinia Pharmaceuticals Inc. announced an oral presentation at the European Alliance of Associations for Rheumatology (EULA R) 2024 taking place in Vienna, Austria June 12-15. The data reinforces… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
